参考文献
[1] Campeau L. Percutaneous radial artery approach for coronary angiography[J].Cathet Cardiovasc Diagn,1989,16(1):3⁃7.
[2] Kiemeneij F, Laarman GJ. Percutaneous transradial artery approach for coronary stent implantation[J]. Cathet Cardiovasc Diagn, 1993,30(2):173⁃178.
[3] 陈伟伟,高润霖,刘力生,等《. 中国心血管病报告2017》概要[J]. 中国循环杂志,2018, 33(1): 1⁃8. DOI: 10.3096 / j. issn. 1000⁃3614.2018.01.001.
[4] Li J, Li X, Wang Q, et al. ST⁃segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE⁃Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data[J].Lancet, 2015,385(9966):441⁃451. DOI:10.1016/S0140⁃6736(14)60921⁃1.
[5] 中国冠状动脉慢性闭塞病变介入治疗俱乐部. 中国冠状动脉慢性完全闭塞病变介入治疗推荐路径[J]. 中国介入心脏病学杂志, 2018, 26(3): 121⁃128. DOI: 10.3096 / j. issn. 1004⁃8812.2018.03.001.
[6] Chen SL, Ye F, Zhang JJ, et al.DK crush technique: modified treatment of bifurcation lesions in coronary artery[J].Chin Med J (Engl), 2005,118(20):1746⁃1750.
[7] Chen SL, Xu B, Han YL, et al. Clinical outcome after DK crush versus culotte stenting of distal left main bifurcation lesions: the 3⁃year follow⁃up results of the DKCRUSH⁃III study[J]. JACC Cardiovasc Interv, 2015,8(10):1335⁃1342. DOI:10.1016/j.jcin.2015.05.017.
[8] Fan L, Chen L, Luo Y, et al. DK mini⁃culotte stenting in the treatment of true coronary bifurcation lesions: a propensity scorematching comparison with T⁃provisional stenting[J]. Heart Vessels, 2016,31(3):308⁃321.DOI:10.1007/s00380⁃014⁃0611⁃7.
[9] Ge J, Jeremias A, Rupp A, et al. New signs characteristic of myocardial bridging demonstrated by intracoronary ultrasound and Doppler[J].Eur Heart J, 1999,20(23):1707⁃1716.
[10] 血管内超声在冠状动脉疾病中应用的中国专家共识专家组. 血管内超声在冠状动脉疾病中应用的中国专家共识(2018)[J]. 中华心血管病杂志, 2018,46(5) : 344⁃351.DOI: 10.3760/cma.j.issn.0253- 3758.2018.05.005.
[11] Jia H, Dai J, Hou J, et al. Effective anti⁃thrombotic therapy without stenting: intravascular optical coherence tomography⁃based management in plaque erosion (the EROSION study) [J]. Eur Heart J, 2017, 38(11): 792⁃800. DOI: 10.1093 /eurheartj/ehw381.
[12] Tonino PA, De Bruyne B, Pijls NH,et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention[J]. N Engl J Med, 2009, 360(3): 213⁃224. DOI:10.1056/NEJMoa0807611.
[13] Xaplanteris P, Fournier S, Pijls NHJ, et al.Five⁃year outcomes with PCI guided by fractional flow reserve[J].N Engl J Med,2018, 379(3):250⁃259. DOI: 10.1056/NEJMoa1803538.
[14] Xu B, Tu S, Qiao S, et al. Diagnostic accuracy of angiography⁃based quantitative flow ratio measurements for online assessment of coronary stenosis[J]. J Am Coll Cardiol, 2017,70(25):3077⁃3087.DOI:10.1016/j.jacc.2017.10.035.
[15] Ge J, Qian J, Wang X, et al. Effectiveness and safety of the sirolimus⁃eluting stents coated with bioabsorbable polymercoating in human coronary arteries[J].Catheter Cardiovasc Interv, 2007,69
(2):198⁃202.DOI: 10.1002/ccd.20926.
[16] Gao R. Firehawk® sirolimus target⁃eluting coronary stent approved by China Food and Drug Administration[J].Eur Heart J, 2014,35(38):2623⁃2624.
[17] Gao RL, Xu B, Lansky AJ,et al. A randomised comparison of a novel abluminal groove⁃filled biodegradable polymer sirolimus⁃eluting stent with a durable polymer everolimus⁃eluting
stent: clinical and angiographic follow⁃up of the TARGET I trial[J]. EuroIntervention, 2013,9(1):75⁃83. DOI:10.4244/EIJV9I1A12.
[18] Gao R, Yang Y, Han Y, et al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China Trial[J]. J Am Coll Cardiol, 2015, 66(21):2298⁃2309.DOI:10.1016/j.jacc.2015.09.054.
[19] Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimus⁃eluting scaffold versus a metallic everolimus⁃eluting stent for ischaemic heart disease caused by de⁃novo native coronary artery lesions (ABSORB II): an interim 1⁃year analysis of clinical and procedural secondary outcomes from a
randomisedcontrolled trial[J]. Lancet, 2015, 385(9962): 43⁃54. DOI:10.1016/S0140⁃6736(14)61455⁃0.
[20] Kereiakes DJ, Ellis SG, Metzger C, et al. 3⁃year clinical outcomes with everolimus⁃eluting bioresorbable coronary scaffolds: the ABSORB III trial[J].J Am Coll Cardiol, 2017,70(23):2852⁃2862.DOI:10.1016/j.jacc.2017.10.010.
[21] Chen JH, Wu YZ, Shen L, et al.First⁃in⁃man implantation of the XINSORB bioresorbable sirolimus⁃eluting scaffold in China[J]. Chin Med J (Engl), 2015, 128(9): 1275⁃1276. DOI: 10.4103 /0366⁃6999.156155.
[22] Wu Y, Shen L, Ge L, et al. Six⁃month outcomes of the XINSORB bioresorbable sirolimus⁃eluting scaffold in treating singlede novo lesions in human coronary artery[J].Catheter Cardiovasc Interv, 2016,87 Suppl 1:630⁃637.DOI:10.1002/ccd.26404.
[23] Han Y, Xu B, Fu G, et al. A randomized trial comparing the NeoVas sirolimus⁃eluting bioresorbable scaffold and metallic everolimus⁃eluting stents[J].JACC Cardiovasc Interv, 2018,11(3):260⁃272.DOI:10.1016/j.jcin.2017.09.037.